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services the general public residing within or passing through Lilongwe district and serves approximately 1100 STI patients per month.  Currently individuals seeking treatment at the clinic are tested for HIV under an “opt‐out” policy in which they are tested for HIV unless they specifically decline (in contrast to an “opt‐in” policy in which a person must explicitly request to be tested).  During the first year of opt‐out testing, 6602 patients with no previous HIV test were seen.  Of these, 4111 (62%) were tested for HIV, and 1127 (27%) new HIV infections were identified.  Approximately 5 new infections are identified in the clinic each day.  Each of these newly diagnosed individuals has sexual partners who require evaluation for therapy, if they are also infected, or prevention interventions, if they are uninfected.  
HIV Testing and Importance of Early Diagnosis HIV‐infected individuals seeking care at an STI clinic are at high risk for onward transmission.   STIs can facilitate HIV transmission by invoking more infectious HIV variants7 and increasing HIV concentrations in genital lesions and semen8, 9.  The risk of HIV transmission is directly related to viral burden, and increases markedly with increasing concentrations10.  Partners of these individuals are exposed to high levels of virus and it is therefore imperative to reach them for evaluation for treatment (if they are also infected) or prevention measures (if they are uninfected).  In spite of the high prevalence of infection, many HIV‐1‐infected in this region of the world continue to go undiagnosed. Even when diagnosis occurs promptly, many persons are lost to the health care system and present for care too late for the benefits 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of antiretroviral therapy 11‐13.  Late presentation is associated with depleted CD4 counts, and CD4 count at the initiation of therapy predicts survival 14, 15.   Late presenters have significant short‐term mortality16‐18 and early diagnosis of HIV infection is increasingly understood as the critical gateway to providing individuals with ART and effective prevention and care.  The majority of HIV transmission occurs from persons unaware they are infected 19; therefore, it is an important public health responsibility to increase the percent of HIV‐infected individuals who know their status.  Treatment is currently a reality for HIV infected individuals in Malawi.  Malawi began a national scale‐up of antiretroviral treatment (ART) in 2004, and has since started over 100,000 people on treatment 5, 20.  Effective partner notification will increase HIV testing rates, providing an opportunity earlier diagnosis and referral for treatment.    
HIV Partner Notification The purpose of HIV partner notification is to increase HIV diagnosis and referral.  Partner notification involves informing sexual partners of HIV‐positive persons that they have been exposed and encouraging them to seek counseling, testing and other prevention and treatment services.  Two important goals of HIV partner notification are to provide earlier diagnosis and referral to appropriate services for those who are infected, and to provide testing and prevention counseling to HIV negative individuals and promote risk reduction 21, 22. 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The three main methods of partner notification are passive referral, contract referral, and provider referral23.  Passive referral is currently the standard of care, in which the patient is encouraged to counsel partners concerning their possible exposure to HIV by themselves.  Under contract referral health care providers of the index patient obtain names and locations of the partners, but allow the source patient a period of time to contact and notify sexual partners him/herself. If partners are not notified and tested within this time period, the health care providers will contact and counsel the partners, advising them they have been exposed to HIV while maintaining the anonymity of the index case.  Under provider referral, HIV positive people give the names and locations of their sexual partners to a health care provider, who then contacts the partners directly, advising them they have been exposed to HIV while maintaining the anonymity of the index case.  In contrast to passive referral where the index patient must notify the partner themselves, the anonymity of the index case is maintained during contact with the partners during contract referral and provider referral.  Both contract referral and provider referral demand more resources than passive referral and requires the cooperation of the index case.    Passive notification is currently the standard of care in Malawi.  In the KCH STI clinic, newly diagnosed patients are provided notification cards to give to their partners.  The notification card instructs the partner to return to the clinic, and allows partners to bypass the regular reception and waiting room to receive priority counseling and testing.  This method of passive referral only rarely leads to presentation of the partner.  Less than 1% of all clinic visits at KCH are referred partners (for all STI syndromes, 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including HIV).  The current National Malawi HIV/AIDS Testing and Counseling Policy on disclosure indicates that counselors should ‘advise and assist’ HIV positive individuals to notify partners (passive notification), but also identified a need to ‘develop appropriate and explicit guidelines outlining how, when and to whom beneficial disclosure by a health care worker may be made.’   
Evidence on Partner Notification in Developed Countries Public Health partner notification programs were incorporated into U.S. and British syphilis control efforts in the 1930s and 1940s, and were later expanded to include gonorrhea, chlamydial infection, and HIV.  In the United States, partner notification has been required of state and local health departments as a condition for receiving federal HIV prevention funds since the 1980s.  Currently, local and state health departments that receive funding from the CDC are required to include partner counseling and referral services (PCRS) in their HIV prevention programs24.  In American and European settings, approximately 20% of partners tested through partner notification services are new HIV diagnoses.  An evaluation of the success of PCRS in North Carolina revealed that 20.5% of tested partners of HIV index patients had HIV infections that were previously undiagnosed25 and 22% of partners referred through partner notification services in San Francisco were new HIV diagnoses26.  A review of partner notification in 6 European countries uncovered new HIV infections in 21% of current partners and 10% of ex‐partners27 and 25% of tested partners in Scotland were new HIV infections28.  The yield of new diagnoses is potentially much greater in the higher prevalence African settings. 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Passive referral in developed countries results in few partners seeking counseling and testing.  In a small study in the U.S. comparing patient referral with contract referral, partner notification and uptake of HIV testing increased with contract referral 29.  In the contract referral arm, 50% of partners were successfully notified and of those, 46% accepted HIV testing in the contract referral arm.  In contrast, only 7% of partners were notified in the passive referral arm.  In an evaluation of a public health partner notification only 20% of locatable partners received counseling through patient referral30.  Similar results with passive notification were observed in the UK. Among 501 newly infected HIV‐positive patients, only 27 partners received HIV counseling and testing31.  Active partner notification services has increased receipt of HIV counseling and testing among sexual partners of patients with new HIV diagnoses, and those who successfully notify their partners are more likely to disclose their HIV status to future sex partners.  In addition, relationship dissolution is lower and condom use is higher when partner notification messages successfully reach the partner32.  
Partner Notification and HIV Disclosure in Developing Countries The effectiveness of HIV partner notification in developing countries is unknown since, to date, partner notification strategies have not been evaluated in developing countries33.   However, patients in STI clinics report provider‐assisted referral would be helpful for STI partner notification and partner referral 34.  HIV partner notification has recently been implemented in Cameroon and to date over 2000 partners have been 
  10 
evaluated 35, supporting the feasibility of partner notification in Africa.  Additionally, descriptive studies demonstrate benefits to partner disclosure in African settings.    Partner disclosure in the antenatal setting led to increased condom use 4, 36‐38 and greater use of antiretroviral drugs to avoid perinatal transmission 4.  Partner disclosure in the post‐partum setting also appeared to influence decisions regarding breastfeeding 
37 and subsequent pregnancies 38, although others observed no effect of disclosure on subsequent reproductive behavior 39.  Partnership dissolution is low after disclosure in the antenatal or postnatal setting 36, 40.    Disclosure to a main partner by women attending HIV Care facilities report safer sexual behaviors, including increased condom use and abstinence41.  Non‐disclosure among men and women accessing HIV services in South Africa was associated with increased multiple partnerships and lower condom use compared to those who had disclosed.  In a community sample of South African men and women disclosure to partners was associated with lower risk behavior, including increased condom use and decreased number of sexual partners42.  These studies demonstrate the potential benefits for partner notification, such as risk behavior change when both partners know their status and making informed reproductive health choices, particularly the more contemporary studies in which treatment options were available.  However, all are observational, all rely on self‐





















































































All variables were entered into the full model.   We constructed a simplified final model using backwards selection with a predetermined stopping rule of p = 0.10 to maintain predictive ability and reduce the likelihood of omitting important variables.  Nested models were compared using likelihood ratio tests.  We examined the model for collinearity and overly influential covariate patterns 54.  A risk score algorithm was developed for Model 1 to predict the risk of a partner not reporting for counseling and testing among partner’s who were not traced in the community. In order to create a simple instrument that can be applied in the field we assigned each variable in the final Model 1 a predictor score equal to its beta coefficient (natural log of the adjusted odds ratio) rounded to the nearest integer 55.  We summed the risk scores to obtain a risk score for each participant. We assessed model accuracy and risk score accuracy using area under the receiving operator characteristics curves.  We calculated the proportion of partners requiring tracing by a community counselor under each risk score scenario as:            (equation 3.3) Where Ptraced = proportion of partners traced, Se = sensitivity, Sp = specificity, and PNR= proportion failing to report  We calculated the proportion of partners traced unnecessarily as: 
Punnecessary = (1− Sp) × (1− PNR )            (equation 3.4) 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Where Punnecessary = proportion of partners traced unnecessarily, Se = sensitivity, Sp = specificity, PNR= proportion failing to report  In the clinical trial, the proportion of partners who tested under universal provider assisted referral was 51%56.  The estimated proportion of partners tested under each risk score scenario was calculated as:   
Ptested = (0.51× Ptraced ) + (Sp × (1− PNR ))         (equation 3.3) where Ptested = estimated proportion of partners tested, Sp = specificity, PNR= proportion failing to report, Ptraced = number of partners traced  A false positive was a partner who was identified using the risk score algorithm for provider‐assisted referral, but would have reported to the clinic on their own.  A false negative is a partner who was not identified for provider‐assisted referral using the risk score algorithm and did not receive testing. The relative costs of false negatives and false positives were compared at different model cut‐points using the formula: 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Persons with newly diagnosed HIV infection at Kamuzu Central Hospital and Bwaila Hospital outpatient STI clinics in Lilongwe, Malawi were recruited. All patients presenting to these STI clinics are tested for HIV under an opt‐out protocol that includes group pre‐test counseling, rapid tests (Determine HIV‐1/2, Abbott Laboratories and Unigold, Trinity Biotech), and individual post‐test counseling. Patients from Lilongwe who had a positive HIV test result for the first time, were 18 years or older, had been sexually active in the last 90 days, were willing and able to provide locator information for their sexual partners, and agreed to be randomized to a method of partner notification were eligible to participate.    
Study procedures Index patients provided informed consent and answered a short questionnaire about recent sexual behavior, including the number, type, and locations of sexual partners in the past three months. All were provided referral cards to give to their partners, were counseled on the importance of safe sex behavior, staged using WHO clinical staging criteria, and had blood drawn for CD4 counts using flow cytometry (Epics‐XL, Coulter). Index patients were then randomized to passive, contract, or provider referral using a permuted block design with randomly allocated block sizes of six, nine, and twelve, stratified by sex and study site. The passive referral group was responsible for notifying their partners themselves. The contract referral group was given seven days to notify their partners, after which a health care provider contacted partners who had not reported for counseling and testing. Notification in the provider referral group occurred within 48 hours. Randomization assignment was concealed in a sealed envelope until 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the end of the enrollment visit (after all partner data and locator information had been collected).    Index patients returned to the clinic two weeks after enrollment to receive CD4 test results and initiate HIV care. Index patients eligible for antiretroviral therapy based on CD4 count or WHO clinical stage were referred to a convenient HIV treatment clinic. Index patients were also asked whether their partners were notified, how their partners were notified, and their knowledge of their partners HIV counseling and testing behavior.   Incoming patients were identified as partners if they presented a partner referral card or their name was found on the log of named partners during cross‐checking. Partners were tested for HIV under the opt‐out testing protocol that is standard of care in the clinic. HIV antibody‐negative or ‐indeterminate specimens were tested for the presence of HIV RNA using the ultrasensitive Roche Amplicor Monitor HIV RNA assay.  
Statistical Analysis Partners were considered “locatable” if the index was able to provide locator information, including name and where they could be found, during enrollment. Main partners were defined as spouses and live‐in partners, or boyfriend/girlfriend if the index did not name a spouse or live‐in partner. Casual partners included regular casual partners, infrequent casual partners, sex workers and boyfriend/girlfriend if the index already had a spouse. Partners were considered new HIV diagnoses if they were testing 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for the first time or their previous test result had been negative. The primary outcome was partner visit to the clinic during the 30 days following index enrollment.    Based on the assumption of one partner per index client and 15% of the partners in the passive referral arm presenting, the overall sample size of 240 index patients with 80 index patients in each arm was calculated prior to the start of the study to have 85% power to detect (α=0.05, two‐sided test) a 25% difference between passive referral and the two active referral study arms (contract or provider).   Unconditional logistic regression with a cluster robust variance estimator51 was used to calculate 95% confidence intervals for the proportion of locatable partners visiting by arm and risk differences and relative risks of visiting for the two active referral arms versus the passive referral arm. Pre‐planned subgroup analyses were performed by sex and type of partner (main partner vs. casual partner). Planned sensitivity analyses where the unit of analysis was the index case (rather than the named partner of an index case) and the primary outcome was defined as at least one partner visiting the clinic were conducted. Time to presentation among all locatable partners was analyzed using Cox Proportional Hazards Regression with robust confidence intervals52 to account for clustering by index patient. The Wald chi‐square test was used to compare the effect of method of partner notification on time to presentation. The proportional hazards assumption was evaluated using the Cox test and visually by plotting the ln(‐ln(survival)) against ln(time).  We used Stata version 10 (StataCorp, College Station, Texas, USA) for all analyses. 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Overall, 302 partners were named including 219 (73%) main partners. The index reported planning to have sex again with 220 (73%) of the partners. The median partnership duration was 24 months (IQR: 3‐84). Condom use was low; only 15% of index patients reported condom use at last sex and 77% reported never using condoms with any partner [Table 4.2].    Among 302 named partners, locator information was available for 252 (84%). Compared to non‐locatable partners, locatable partners were more likely to be spouses (64% vs. 0%), male (56% vs. 10%), and have a duration of the partnership >1 month (79% vs. 7%).   Overall, 107 (35%) partners visited the clinic. Partner presentation, including non‐locatable partners, was 22% (95% CI 13 – 30%) in the passive referral arm, 48% (95% CI 38 – 58%) in the contract referral arm, and 37% (95% CI 28 – 45%) in the provider referral arm.  Restricting the analysis to locatable partners, the proportion of partners visiting was 24% (95% CI 15 – 34%) in the passive referral arm, 51% (95% CI 41 – 62%) in the contract referral arm, and 51% (95% CI 40 – 62%) in the provider referral arm [Table 4.3]. Among locatable partners, those in the contract and provider referral arms were both 2.1 times as likely to visit the clinic compared to those in the passive referral arm (contract versus passive: RR 2.1; 95% CI 1.4‐3.2; p< 0.001; provider versus passive: RR 2.1; 95% CI 1.4‐3.2; p<0.001). The proportion of partners visiting the clinic was 27% higher in both the contract and provider referral arms, as compared to passive referral (contract versus passive: RD 27%; 95% CI 13‐41% p< 0.001; provider 
  38 
versus passive: RD 27%; 95% CI 13‐41%; p<0.001). The proportion of index patients with at least one partner visiting the clinic for counseling and testing was 26% (95% CI 16 – 35%) in the passive referral arm, 55% (95% CI 44 – 66%) in the contract referral arm, and 51% (95% CI 40 – 62%) in the provider referral arm.  Time to presentation among partners was associated with method of partner notification (p<0.001) [Figure 4.2]. The hazards were not proportional over time so hazard ratios were estimated separately for partner visit in the first seven days and after seven days. Among locatable partners, the hazard ratio for evaluation in the first seven days for partners in the contract referral arm was 1.4 (95% CI 0.7‐2.6) and 2.1 (95% CI 1.1‐3.7) for partners in the provider referral arm compared to partners in the passive referral arm. After seven days, the hazard ratio for evaluation for partners in the contract referral arm was 6.6 (95% CI 2.3‐18.8) and 4.3 (95% CI 1.4‐13.0) for partners in the provider referral arm compared to partners in the passive referral arm. The median time between enrollment of the index and partner presentation among those who visited the clinic was three days in the passive referral arm (IQR 2‐7 days), seven days in the contract referral arm (IQR 3‐11 days), and four days in the provider referral arm (IQR 2‐8 days). In the contract referral arm, 30 (67%) partners who reported for counseling and testing were traced by a community counselor.    The acceptance rate for HIV testing among partners seen in the clinic was high. Overall, 104 (97%) of partners accepted HIV testing, and 67 (64%) tested HIV‐positive; one partner was identified as acutely infected based on HIV RNA in the blood, lack of HIV 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antibodies and subsequent seroconversion. Fifty‐four (81%) were new HIV diagnoses by self‐report. Twelve partners (15%; 95% CI 7‐22%) in the passive referral arm, 21 partners (24%; 95% CI 15‐33%) in the contract referral arm, and 21 partners (26%; 95% CI 16‐35%) in the provider referral arm were new HIV diagnoses. The median CD4 count among partners was 344 (range: 47 ‐ 940). Twenty‐eight percent of partners were eligible to start antiretroviral therapy based on the current Malawi treatment guidelines (CD4 < 250 cells/mm3) [Table 4.4]. Most partners reported only a single sexual partner, with 85 (82%) reporting one sexual partner in the previous 3 months.    Index patients and partners reported two social harms. In one instance, a female index reported her male partner abandoned her when she disclosed her HIV status. In the other, a female partner called the police when the community counselor visited the home. The situation was quickly resolved and the partner later sought counseling and testing at the clinic.  
Discussion The HIV pandemic in Africa has been unabated for more than 20 years, despite massive prevention efforts59. The introduction of ART in recent years has undoubtedly benefited many patients, but frequently patients receive therapy too late for maximal benefit. Currently, access to ART is increasing, and ART as a prevention tool has been supported60. However, optimal treatment and prevention require that infected people know their status. To achieve this goal, novel strategies of massive household testing61 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and couples counseling62 have been investigated. Partner notification, a logical and potentially critical intervention, has not been evaluated.       In Malawi, we observed that provider‐assisted methods of HIV partner notification are feasible, acceptable and effective among STI clinic patients. A high proportion of eligible patients participated and provided accurate partner locator information. Provider‐assisted partner notification was implemented without difficulty and was supported by clinic staff. Provider‐assisted partner notification resulted in more partners receiving counseling and testing services than passive referral, the current standard of care.  Partner notification increased early referral to care. About one quarter of infected partners were eligible to begin ART based on current Malawian national guidelines and half of all infected partners had a CD4 count of 350 cells/mm3 or less. Given that mortality is significantly increased in late presenters and baseline CD4 count is a strong predictor of response to antiretroviral therapy and mortality14, the population of partners identified in this study are highly likely to benefit from knowledge of their status.    Prevention of HIV transmission within serodiscordant partnerships is an important HIV prevention strategy. In our study, 45% of tested partners were in a serodiscordant relationship. Serodiscordant couples receiving couples counseling report increased condom use and lower rates of seroconversion63, 64. Partner notification may be an 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effective strategy to facilitate both individual behavior change among uninfected individuals and increase couples counseling in the region.  Provider‐assisted partner notification is an important method to increase testing among male partners. While 50% of male partners sought evaluation in the contract and provider referral arms, only 15% did in the passive referral arm. Extending provider‐assisted notification to antenatal clinic settings may be a novel way to increase male involvement in prevention of mother‐to‐child transmission programs. To date male involvement in PMTCT has been low in sub‐Saharan Africa65, 66 and continues to be difficult to implement. When male partners are involved or couples counseling is provided during PMTCT, HIV testing uptake is higher and women are more likely to implement PMTCT treatment and care interventions67.    The potential for social harms is a key concern in partner notification programs. However, the index patients and partners in our study reported only two social harms throughout the entire study period, a 0.5% cumulative incidence. Experience elsewhere in the region suggests social harms are not increased among women in couples antenatal testing compared to women who do not disclose to their partner68, and in South Africa men and women who disclosed their HIV status reported an increase in social support42. Experience in the U.S. suggests partner notification does not increase partnership dissolution32. However, prior history of abuse in a relationship following disclosure of HIV status is a strong predictor of reported physical or emotional abuse following disclosure69. Screening for intimate partner violence and emotional abuse 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could be incorporated into post‐test counseling and further operations research will be necessary to investigate the effect of provider assisted partner notification on social harms in a variety of African settings.    The STI clinic population in this study may not be representative of all new HIV diagnoses. Partners may be more motivated to respond to notification messages because of potential for STI treatment. However, partners of persons testing positive while seeking treatment for STIs are important to target for increased counseling and testing, as infectiousness is high in HIV‐infected individuals with a concurrent STI. Implementation of HIV partner notification in STI clinics should go along with partner notification for STI treatment.  Successful partner notification is contingent on index patients providing locator information for their partners and community counselors successfully locating partners. In our study population, index patients often did not know the name or location of one‐time or short‐term partners. These partners are unlikely to be notified by the index and are unable to be traced by community counselors. Unfortunately, this group may represent high transmitter populations. As provider‐assisted partner notification techniques are further refined in this setting, techniques to elicit more accurate locator information and find partners will be improved, and a larger proportion will be expected to be located and receive counseling and testing.  















  Passive Referral  Contract Referral  Provider Referral 
  (N = 82)  (N = 88)  (N = 82) 
  
Percent 
Return (95% CI)  
Percent 
Return (95% CI) RD (95% CI) RR  (95% CI)  
Percent 
Return (95% CI) RD (95% CI) RR (95% CI) 
Overall  24 (15-34)  51 (41-62) 27 (13-41) 2.1 (1.4-3.2)  51 (40-62) 27 (13-41) 2.1 (1.4-3.2) 
                  
Men  16 (5 -26)  52 (38-66) 37 (19-54) 3.4 (1.6-7.0)  51 (37-65) 36 (18-53) 3.3 (1.6-6.9) 
Women  35 (20-51)  50 (34-66) 15 (-7-37) 1.4 (0.8-2.4)  51 (35-68) 16 (-6-39) 1.5 (0.9-2.5) 
                  
Main Partner  28 (17-38)  55 (43-66) 27 (12-43) 2.0 (1.3-3.1)  54 (43-66) 27 (11-42) 2.0 (1.3-3.0) 
Casual Partner  8 (0-22)  33 (9-58) 25 (-3-54) 4.3 (0.6-32.5)  30 (1-59) 22 (-9-54) 3.9 (0.5-32.1) 
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Table 4.4. Partner HIV test results and CD4 counts (cells/mm3) (n=107)  Partner Results  N   n  % Partners tested   107  104  97% Main partners tested  98  97  99% Casual partners tested  9  7  92% Partners with positive test results   104  67  64% Main partners with positive test results  97  63  64% Casual partners with positive test results  7  4  57% Partner CD4 count [median cells/mm3 (IQR)]  344 (225‐450)     CD4 < 250  67  17  29% CD4 250‐350  67  13  22% CD4 > 350  67  29  49% 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Figure 4.1. Study Population   
357 HIV positive tests in KCH outpatient STI unit
44 HIV positive tests in Bwaila outpatient STI
267 eligible for partner noti!cation
240 index enrolled
77 enrolled passive referral
93 partners named
82 locatable partners named
82 enrolled contract referral
94 partners named
88 locatable partners named
81 enrolled provider referral
115 partners named
82 locatable partners named
134 ineligible:
Came as a couple
Live outside Lilongwe
No sex in the previous 3 months





Didn’t want to notify partners
Afraid to notify partners
































In order to create a simple instrument that can be applied in the field we assigned each variable in the final model a predictor score equal to its beta coefficient (natural log of the adjusted odds ratio) rounded to the nearest integer 55.  We summed the risk scores to obtain a risk score for each participant.  We calculated the proportion of partners requiring tracing by a community counselor under each risk score scenario as:          (equation 5.1) Where Ptraced = proportion of partners traced, Se = sensitivity, Sp = specificity, and PNR= proportion failing to report  We calculated the proportion of partners traced unnecessarily as: 
Punnecessary = (1− Sp) × (1− PNR )         (equation 5.2)  Where Punnecessary = proportion of partners traced unnecessarily, Se = sensitivity, Sp = specificity, PNR= proportion failing to report  In the clinical trial, the proportion of partners who tested under universal provider assisted referral was 51%56.  The estimated proportion of partners tested under each risk score scenario was calculated as:   
Ptested = (0.51× Ptraced ) + (Sp × (1− PNR )       (equation 5.3) where Ptested = estimated proportion of partners tested, Sp = specificity, PNR= proportion failing to report, Ptraced = proportion of partners traced 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A false positive was a partner who was identified using the risk score algorithm for provider‐assisted referral, but would have reported to the clinic on their own.  A false negative is a partner who was not identified for provider‐assisted referral using the risk score algorithm and did not receive testing. The relative costs of false negatives and false positives were compared at different model cut‐points using the formula:  






















Partner Characteristics     Partner sex     Male  93  45.3% Female  77  54.7% Partner type     Main partner  142  83.5% Non‐main partner  26  16.5% Length of partnership     < 6 months   45  26.5% 6 – 24 months  42  24.7% > 24 months   83  48.8% Face transport barriers     Yes  84  49.1% No  86  50.9% 




Table 5.2. Unadjusted and adjusted odds ratios and risk scores for index and partner characteristics predicting partner HIV counseling and testing (n = 170) Predictor  OR   95% CI  aOR   95%CI  β   Score 
Partner Characteristics             Sex             Female  1.0    1.0       Male   2.3   1.1 – 4.8  3.5   1.6 – 8.3  1.3  1 Type of Partner             Main partner  1.0           Non‐main partner  8.8   1.2 – 67.4         Partnership duration             < 6 months  6.4   1.8 – 22.5  10.5   2.8 – 39.9  2.4  2 6 – 24 months  2.3   0.9 – 5.8  2.6   1.0 – 6.9  0.9  1 > 24 months  1.0    1.0       Faced transport barriers             Yes  1.0   0.5 – 2.0         No  1.0           








Proportion of partners tested#  False Positives**  False Negatives††  Total Errors‡‡ 
Cases of HIV missed relative to universal provider‐assisted referral§§ 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partners.  Immediate provider‐assisted referral led to the most rapid evaluation of partners.  However, the rate of partner return was similar between contract referral and provider referral after seven days.  Partner notification uncovered many persons with previously unidentified  HIV infection.  Provider‐assisted methods of partner notification resulted in more partners receiving testing, and these methods identified a greater number of new infections per index.  Partner notification helped many partners access treatment earlier, as approximately a quarter of all partners were already eligible for treatment based on the Malawi treatment guidelines (CD4 count < 250 cells/mm3).  More than half of tested partners had CD4 counts less than 350 cells/mm3, the cut point for ART treatment eligibility currently being discussed by the Ministry of Health for revised treatment guidelines.  Among partners given the opportunity to present for testing on their own (partners of indexes assigned to passive and contract referral), male partners, short‐term partners, casual partners, and partners of more educated index patients were unlikely to present on their own.  Using a risk score algorithm, partners unlikely to present on their own can be referred for immediate provider‐assisted referral and very few partners who are likely to present on their own will be traced unnecessarily.  All partners are at high risk of HIV infection and it is critical to reach them with testing, prevention, and treatment services. 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Strengths Provider‐assisted methods of HIV partner notification are new to sub‐Saharan Africa.  While it has been implemented in a limited area in West Africa35, the effectiveness has never been evaluated.  Our work provides the first data on the effectiveness of different methods of HIV partner notification in a region of the world greatly affected by HIV.  The study design allowed us to directly compare the effectiveness of three different strategies of partner notification.  We minimized the potential effects of confounding variables and reduced selection bias by randomizing index participants to a particular method of partner notification rather than allowing them to choose.  While some selection bias may still be present, only a small proportion of eligible index patients refused participation.  HIV partner notification is a topic directly relevant to the local population.  The vast majority of HIV transmission in Malawi is through heterosexual sex, and the sexual partners of those diagnosed with HIV need to be evaluated for antiretroviral therapy, if infected, or targeted with prevention programs so that they can stay uninfected.  There is currently no national policy on HIV partner notification; the HIV counseling and testing guidelines only state that there is a need to provide evidence on when and to whom provider‐assisted referral should be made.  Providers have long been frustrated by the low rate of partner counseling and testing and are enthusiastic and eager to implement new ways to increase the numbers of partners receiving important 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All partner notification activities, including counseling, collecting locator information, and finding partners in the community were conducted by highly experienced providers trained in research methods.  They are experienced in collecting locator information from clients and counseling patients about procedures.  The effectiveness of provider‐assisted partner notification will also reflect the amount of training and skill of the counselors.  Successful partner notification is contingent on index patients being able to provide locator information for their partners and community counselors being able to successfully locate partners.   In order to be “locatable” an index must know the partner’s name and be able to describe where they live or where they can be found.  In our study population, locator information was often unavailable for one‐time or short‐term partners.  These partners are unlikely to be notified by the index and are unable to be traced by community counselors.  This is unfortunate because this group likely represents high transmitter populations. Overall, half of locatable partners who received provider‐assisted referral sought counseling and testing, suggesting partner notification may be most effective in longer‐term, more stable partnerships.  Although we do not know the proportion of partners notified in the passive referral arm, in the contract and provider referral arms 72/95 (76%) of partners who were successfully notified by a provider returned to the clinic for counseling and testing.  As provider‐assisted partner notification techniques are further refined in this setting, techniques to 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elicit more accurate locator information and find partners will be improved and a larger proportion will be expected to be located and return for counseling and testing.  While few social harms were observed in our study population, the length of follow‐up was limited.  Additionally, we do not have social harms data on the partners who did not report for testing and counseling at the clinic.  Index patients and partners who reported were counseled extensively to report any experiences of social harms to clinic staff. However, a longer period of follow‐up is necessary to thoroughly assess the social impact of partner notification.  The small number of events limits the power of predictive modeling.  Only 37 partners reported for counseling and testing on their own, which was used to develop a risk score.  Many covariates were hypothesized to influence the probability of a partner returning and partner HIV test result.  The ability of a model to predict future events is reduced when too many parameters are used to estimate for the amount of information in the data.  Internal validation using bootstrapping was performed. However, the precision and optimism may be exaggerated by the over‐fitting of the model.  The model should be refined in future, larger studies in order to be useful as a clinical screening tool.  The primary objective of the predictive modeling is to elucidate partner characteristics associated with partner testing and to use the risk score to target immediate provider‐assisted referral.  Very little is known about partner testing in sub‐Saharan Africa and these characteristics will continue to be refined in practice as partner notification is implemented in the region. 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in a variety of African settings 72, 73.  Therefore, prevention of HIV transmission within sero‐discordant partnerships is an important HIV primary prevention strategy.  Sero‐discordant couples receiving couples counseling report increased condom use and lower rates of seroconversion64, 74, 75 and modeling suggests couples counseling in sero‐discordant couples could reduce transmission rates by up to 60%76.  Couples counseling helps create a safe environment for disclosure of HIV status among partners and can facilitate communication and cooperation required for risk reduction or treatment and care decisions as well as family planning.   Increasing partner testing is a first step towards increasing prevention and treatment activities.  Partner notification could be expanded to offering counseling and testing to households and provide a gateway to high‐risk social networks.  Index patients and their sexual partners can be asked to identify and refer others in their social networks for HIV counseling, testing, and treatment and prevention services.  Social networks strategies have been used successfully to identify undiagnosed cases of syphilis 77 and HIV 78, 79.  Since members of the same social group often display similar sexual risk behaviors, social network strategies have been more effective at identifying new HIV diagnoses than traditional testing and counseling sites. 78 Therefore, extending partner notification to the sexual and social networks of the partner may be an efficient and high yield approach to identifying undiagnosed HIV infection and providing HIV testing and counseling services to high‐risk populations. 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As partner notification is implemented on a wider scale, predictive models to direct provider‐assisted referral should be re‐examined and refined.  The analyses conducted as part of this clinical trial should be used to guide new models and risk score development.  These models should be validated in future populations and a variety of populations receiving partner notification services.  These data have implications for HIV testing policy in Malawi.  Currently, provider‐assisted partner referral procedures have not been officially developed, although a need for the development of “appropriate and explicit” guidelines has been stated.  The effectiveness data were disseminated locally to the Malawi Ministry of Health, including the Testing Advisor and the Director of HIV/AIDS programs.  The Ministry’s primary interest was the impact of partner notification programs on the national treatment programs.  The Ministry also asked questions regarding who they should target with partner notification.  Both the effectiveness data from the clinical trial and the predictive model will provide valuable information as HIV testing guidelines are revised in Malawi.  Additionally, the cost‐effectiveness of the different strategies of partner notification should be examined and continually evaluated as partner notification is implemented on a wider‐scale both in Malawi and elsewhere in the region.  Continued collaboration with policy‐makers will be crucial to ensure the data are used to inform policy.    Despite the push for increased testing, an unacceptably high proportion of infected persons in Africa do not know their status.  HIV partner notification is an important 











Consent to Participate in a Research Study 




IRB Study #08-0862 
Consent Form Version Date: June 24, 2009  
Title of Study: Operations Research to Determine the Community Acceptability and Most 
Effective Method of HIV Partner Notification at Kamuzu Central Hospital STI Clinic, 
Lilongwe, Malawi 
 
Principal Investigator: Gift Kamanga 
UNC Project, Lilongwe Department: STD Clinic Manager 
UNC Project, Lilongwe Phone number: 01-755-056 
Co-Investigators: Francis Martinson, Clement Mapanje, Lillian Brown, Bill Miller, Audrey 
Pettifor and Irving Hoffman  
Funding Source: Malawi National AIDS Commission and UNC Project, Lilongwe 
Study Contact telephone number and email: 
Gift Kamanga 01-755-056, gkamanga@unclilongwe.org.mw;   
Francis Martinson 01-755-056, fmartinson@unclilongwe.org.mw 
______________________________________________________________ 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason. 
 
Research studies are designed to obtain new knowledge that may help other people in the 
future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Deciding not to be in the study or leaving the study before it is done will not affect your 
relationship with the researcher, your health care provider, or the UNC Project, Lilongwe.  If 
you are a patient with an illness, you do not have to be in the research study in order to 
receive health care.  
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
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The purpose of this research study is to learn the best way HIV positive persons should notify 
their sexual partners that have been exposed to HIV. This is called Partner notification. 
Partner notification involves informing the sexual partners of HIV-positive persons that they 
have been exposed and encouraging them to seek HIV counseling, testing and other 
prevention and treatment services.  The Malawi National HIV/AIDS Policy and Testing and 
Counseling Guidelines state that partner notification methods should be used to help HIV 
positive persons notify their partners, however we don’t know which method is the most 
effective and acceptable in Malawi. 
 
You are being asked to be in the study because you had a positive HIV test at our clinic today.   
 
Are there any reasons you should not be in this study? 
You should not be in this study if you are not willing to provide the names and locations of 
your sexual partners or if you are not willing to return to the clinic in 2 weeks for a follow-up 
visit. 
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 240 people in this research 
study. 
 
How long will your part in this study last?  
Your participation in this study will last approximately 2 weeks.  Today’s visit will last about 
1 hour and another final 1 hour visit will be in 2 weeks time.  
 
What will happen if you take part in the study? 
Today you will talk to an HIV counselor on the importance of safe sex behavior, will have a 
brief physical exam, blood will be drawn for a CD4 count to determine if you need HIV 
treatment, and you will answer a short questionnaire about recent sexual behavior, including 
the number and type of sexual partners you have had in the past three months.   
 
You will also talk to an HIV counselor about your recent sexual partners, including their 
names and where they can be found.  You will then be assigned by chance, like flipping a 
coin, to one of three study groups: passive referral, contract referral, or provider referral.   
 
If you are assigned to the passive referral study group you will be given a notification card to 
give to each of your sexual partners.  The partner can then bring the card back to the clinic if 
they visit for HIV testing and counseling services.   
 
If you are assigned to the contract referral study group you will be given notification cards to 
help you notify your partners.  However, if your partners do not come to the clinic for 
counseling and testing within 7 days, a community outreach worker will contact your 
partners.  They will advise your partners that they have been exposed to HIV and urge them 
to visit the clinic for counseling and testing.  Your identity will never be disclosed to your 
partner when they are notified that they have been exposed to HIV.   
 
   
 84 
If you are assigned to the provider referral study group, a community outreach worker will  
contact the partner(s) directly to assure they have been notified as soon as possible.  They 
will be advised that they have been exposed to HIV and encouraged to visit the clinic for 
counseling and testing.  Your identity will never be disclosed to your partner.   
 
You will be asked to return to the clinic in two weeks to receive your CD4 count results and 
to answer a short questionnaire about the partner notification process.  You will be referred to 
the Lighthouse clinic if ARV (HIV) treatment is indicated. 
 
What are the possible benefits from being in this study? 
The benefits to you from being in this study may be to help you notify your sexual partners 
that they may have been exposed to HIV. Malawi may benefit from the results of this 
research by informing policy makers what is the best method of providing partner 
notification to individuals exposed to HIV.  
 
What are the possible risks or discomforts involved with being in this study?  
You may feel embarrassed to answer questions about your sexual behavior.  You can refuse 
to answer any questions asked of you at any time. 
 
We will protect your confidentiality to the greatest extent possible.  Your identity is never 
disclosed to your partner.  If your partner must be contacted in the community we will 
prevent other people (non-partners) from intercepting partner notification messages.  Once a 
partner is located, their identity must be confirmed before continuing and all discussion with 
the community outreach worker must take place in a private place.   
 
Notifying your sexual partner(s) that have been exposed to HIV may cause you social, 
economic, legal or physical harm due to the partner notification process. Our team of 
researchers and counselors will do everything in our power to help you resolve these 
problems if they arise.   
 
If you choose not to be in the study, what other treatment options do you have?  
You do not have to be in this research study in order to receive care at the STI clinic.  
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.   
 
How will your privacy be protected?   
If you decide to be in this study you will be assigned a study ID number.  This number will 
be linked to your name and medical record at the STI clinic only through a separate log book 
that will be kept in a separate locked file. Only the study coordinator will be able to link your 
medical record that has your name on it and your study information that only has your study 
number on it. At the conclusion of the study, this link between your name and number will be 
destroyed.  
 
No subjects will be identified in any report or publication about this study.  In some cases, 
your information in this research study could be reviewed by representatives of the 
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University of North Carolina, research sponsors, or Malawi government agencies for 
purposes such as quality control or safety.    
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include 
the risk of personal injury. If such problems occur, the researchers will help you get medical 
care or counseling and all costs will be paid by the UNC Project, Lilongwe. By signing this 
form you do not give up any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have 
the right to stop your participation at any time. This could be because you have had an 
unexpected reaction, or have failed to follow instructions, or because the entire study has 
been stopped. 
 
Will you receive anything for being in this study? 
You will be reimbursed for your transport expenses to and from the research clinic. The 
average transport reimbursement per visit will be the local equivalent of US$4 at any point in 
time. 
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  All tests, visits or procedures are free of 
charge.  
 
Who is sponsoring this study? 
This research is funded by the Malawi National AIDS Commission and the UNC Project, 
Lilongwe. This means that the research team is being paid by the sponsor for doing the study.  
The researchers do not, however, have a direct financial interest with the sponsor or in the 
final results of the study. 
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, or if a research-related injury occurs, you should contact the 
researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by the Malawi Health Sciences Research 
Committee a Committee that works to protect your rights and welfare.  If you have questions 
or concerns about your rights as a research subject you may contact, anonymously if you 
wish, the chairman, Dr. Charles Mwansambo at 08-826-946.  






   
 86 
 
Signature Page: Consent Form 
 
Title of Study: Operations Research to Determine the Community Acceptability and Most 
Effective Method of HIV Partner Notification at Kamuzu Central Hospital STI Clinic, 
Lilongwe, Malawi 
 
Principal Investigator: Gift Kamanga, STD Clinic Manager 
 
SIGNATURES   
If you have read this consent form, or had it read and explained to you, and you understand 
the information, and you voluntarily agree to the procedures, please sign your name or 
make your mark below. 
 
____________________  ________________________  ______________ 
Participant Name    Participant Signature    Date 
(print) 
 
____________________ ________________________ ______________ 
Study Staff Conducting Study Staff Signature Date   
Consent Discussion (print) 
 
Participant is            literate             illiterate 
 
Witness name, signature and date are required on this form only when the consenting participant is 
illiterate/not able to read. 
 
__________________                                   ____________ 
Participant name (print)                                          Date 
 
Participant name and date written by  ________________________ on 
 ______________ 
(only fill if participant is illiterate) 
 
____________________  ________________________  ______________ 
Witness Name (print)    Witness Signature    Date 
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Consent to Participate in a Research Study 




IRB Study # 08-0862 
Consent Form Version Date: June 24, 2009  
Title of Study: Operations Research to Determine the Community Acceptability and Most 
Effective Method of HIV Partner Notification at Kamuzu Central Hospital STI Clinic, 
Lilongwe, Malawi 
 
Principal Investigator: Gift Kamanga 
UNC Project, Lilongwe Department: STD Clinic Manager 
UNC Project, Lilongwe Phone number: 01-755-056 
Co-Investigators: Francis Martinson, Clement Mapanje, Lillian Brown, Bill Miller, Audrey 
Pettifor and Irving Hoffman  
Funding Source: Malawi National AIDS Commission and UNC Project, Lilongwe 
Study Contact telephone number and email: 
Gift Kamanga 08-870-623, gkamanga@unclilongwe.org.mw;   
Francis Martinson 01-755-056, fmartinson@unclilongwe.org.mw 
______________________________________________________________ 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary.  
You may refuse to join, or you may withdraw your consent to be in the study, for any reason. 
 
Research studies are designed to obtain new knowledge that may help other people in the 
future.  You may not receive any direct benefit from being in the research study. There also 
may be risks to being in research studies. 
 
Deciding not to be in the study or leaving the study before it is done will not affect your 
relationship with the researcher, your health care provider, or the UNC Project, Lilongwe.  If 
you are a patient with an illness, you do not have to be in the research study in order to 
receive health care.  
 
Details about this study are discussed below.  It is important that you understand this 
information so that you can make an informed choice about being in this research study.  
You will be given a copy of this consent form.  You should ask the researchers named above, 
or staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study?  
The purpose of this research study is to learn the best way HIV positive persons should notify 
their sexual partners that have been exposed to HIV. This is called partner notification. 
Partner notification involves informing the sexual partners of HIV-positive persons that they 
have been exposed and encouraging them to seek HIV counseling, testing and other 
prevention and treatment services.  The Malawi National HIV/AIDS Policy and Testing and 
Counseling Guidelines state that partner notification methods should be used to help HIV 
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positive persons notify their partners, however we don’t know which method is the most 
effective and acceptable in Malawi. 
 
You are being asked to be in the study because you are a partner of an HIV infected person 
and have tested either negative or positive or have an unclear result.   
 
Are there any reasons you should not be in this study? 
You should not be in this study if you are not willing to talk about how many persons you 
have had sex with in the last 3 months. 
 
How many people will take part in this study? 
If you decide to be in this study, you will be one of approximately 500 people in this research 
study. 
 
How long will your part in this study last?  
Your participation in this study will last approximately 30 minutes.  
 
What will happen if you take part in the study? 
You will be asked a few questions about your sexual history.  
 
If you tested HIV positive today you will talk to an HIV counselor on the importance of safe 
sex behavior, will have a brief physical exam, and blood (1 teaspoon) will be drawn for a 
CD4 count to determine if you need HIV treatment 
 
If your HIV test today is negative or unclear, blood will be drawn (1 teaspoon) for another 
blood test (RNA)  to determine your final HIV status , and if this extra test shows you are 
newly HIV infected, you will be contacted at home with this information. Either way, 
negative or newly infected you need to protect all sexual acts with condoms. If newly 
infected, you will have a CD4 test to see if you need to start immediately on treatment. 
 
You will be referred to the Lighthouse clinic if ARV (HIV) treatment is indicated. 
 
What are the possible benefits from being in this study? 
The benefits to you from being in this study may be to help you get treatment for HIV if it is 
indicated.  Malawi may benefit from the results of this research by informing policy makers 
what is the best method of providing partner notification to individuals exposed to HIV.  
 
What are the possible risks or discomforts involved with being in this study?  
You may feel discomfort when blood is drawn.  You also may feel dizzy or faint, or 
experience bruising or swelling at the blood drawing  site.  You also may become worried or 
anxious while waiting for your HIV test results.  Trained counselors will be available to help 
you deal with these feelings. 
 
If you choose not to be in the study, what other treatment options do you have?  
You do not have to be in this research study in order to receive care at the STI clinic.  
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What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might 
affect your willingness to continue your participation.   
 
How will your privacy be protected?   
If you decide to be in this study you will be assigned a study ID number.  This number will 
be linked to your name and medical record at the STI clinic only through a separate log book 
that will be kept in a separate locked file. Only the study coordinator will be able to link your 
medical record that has your name on it and your study information that only has your study 
number on it. At the conclusion of the study, this link between your name and number will be 
destroyed.  
 
No subjects will be identified in any report or publication about this study.  In some cases, 
your information in this research study could be reviewed by representatives of the 
University of North Carolina, research sponsors, or Malawi government agencies for 
purposes such as quality control or safety.    
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include 
the risk of personal injury. If such problems occur, the researchers will help you get medical 
care or counseling and all costs will be paid by the UNC Project, Lilongwe. By signing this 
form you do not give up any of your legal rights. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have 
the right to stop your participation at any time. This could be because you have had an 
unexpected reaction, or have failed to follow instructions, or because the entire study has 
been stopped. 
 
Will you receive anything for being in this study? 
You will be reimbursed for your transport expenses to and from the research clinic. The 
average transport reimbursement per visit will be the local equivalent of US$4 at any point in 
time. 
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  All tests, visits or procedures are free of 
charge.  
 
Who is sponsoring this study? 
This research is funded by the UNC Project, Lilongwe. This means that the research team is 
being paid by the sponsor for doing the study.  The researchers do not, however, have a direct 
financial interest with the sponsor or in the final results of the study. 
 
What if you have questions about this study? 
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You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, or if a research-related injury occurs, you should contact the 
researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by the Malawi Health Sciences Research 
Committee a Committee that works to protect your rights and welfare.  If you have questions 
or concerns about your rights as a research subject you may contact, anonymously if you 
wish, the chairman, Dr. Charles Mwansambo at 08-826-946.  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
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Signature Page: Partner Consent Form 
 
Title of Study: Operations Research to Determine the Community Acceptability and Most 
Effective Method of HIV Partner Notification at Kamuzu Central Hospital STI Clinic, 
Lilongwe, Malawi 
 
Principal Investigator: Gift Kamanga, STD Clinic Manager 
 
SIGNATURES   
If you have read this consent form, or had it read and explained to you, and you understand 
the information, and you voluntarily agree to the procedures, please sign your name or 
make your mark below. 
 
____________________  ________________________  ______________ 
Participant Name    Participant Signature    Date 
(print) 
 
____________________ ________________________ ______________ 
Study Staff Conducting Study Staff Signature Date   
Consent Discussion (print) 
 
Participant is            literate             illiterate 
 
Witness name, signature and date are required on this form only when the consenting participant is 
illiterate/not able to read. 
 
__________________                                   ____________ 
Participant name (print)                                          Date 
 
Participant name and date written by ________________________ on ______________ 
(only fill if participant is illiterate) 
 
____________________  ________________________ ______________ 
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Signature Page: Oral Consent Form for study refusers 
 
Title of Study: Operations Research to Determine the Community Acceptability and Most 
Effective Method of HIV Partner Notification at Kamuzu Central Hospital STI Clinic, 
Lilongwe, Malawi 
 
Principal Investigator: Gift Kamanga, STD Clinic Manager 
 
You have decided not to participate in the study but we would like to ask you a few questions 
about why you didn’t want to participate and your feelings about partner notification.  
Knowing reasons why people like yourself might refuse partner notification will help us 
understand which method of partner notification is the most effective and acceptable in 
Malawi. 
Answering these questions will take approximately 15 minutes.  We will not record your 
name or any other identifying information about you.   
 
 
SIGNATURES   
If you have read this consent form, or had it read and explained to you, and you understand 
the information, and you voluntarily agree to the procedures, please mark an ‘X’ in the 
appropriate box below: 
 




If you have read this consent form and explained it to the participant and they demonstrate 







____________________ ________________________ ______________ 
Study Staff Conducting Study Staff Signature Date   
Consent Discussion (print) 
 
 





PARTNER NOTIFICATION STUDY: INDEX PATIENT ELIGIBILITY FORM 
 
 To be asked of participant: 
 
  
1 How old are you? 
 
 ___ ___ years 
 
 
    
2 Is today the first time you had a positive HIV test 
or someone told you that you were infected with 
HIV? 
 □ Yes □No 
 
If No then end of form 
    
3 Have you had sex during the last 3 months?  □ Yes □No 
 
If No then end of form 
    
4 Do you live in Lilongwe City?    □ Yes □No 
 
If No then end of form 
    
5 Are you willing and able to provide information 
about your sexual partners, including names and 
locator information? 
 □ Yes □No 
 
If No then end of form 
    
If participant is less than 18 years old or answered no to any questions above then participant is not 
eligible 
    
6 Is participant eligible?  □ Yes □No 
 
If No then end of form 
    
 To be completed by research staff:   
5 Did the participant provide informed consent for 
study participation? 
 □ Yes □No 
 
If No then end of form 
 
   
Initials  Date 
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PARTNER NOTIFICATION STUDY: INDEX PATIENT ENROLLMENT 
 
KSU ID:  
 
Part 1. Demographic Data 
 
Item Question  Response 
1 Indicate client sex  □ [0] Male  □ [1] Female  
2 Indicate STI diagnosis  (from KSU CRF)  
□ [0] No STI diagnosed 
□ [1] GUD     □ [2] AVD   □ [3] BU    □ [4] UD  
□ [5] PRUD   □ [6] LAP    □ [7] SS    □ [8] BA  
□ [9] GW       □ [10] OTHER STI    
 
3 What is your date of birth?   ___ ___    ___ ___ ___   ___ ___    D     D       M    M    M Y    Y    
4 Age:  ___ ___ years 
5 What is the highest level of education you have completed?  
 
□ [0] Never attended school 
 
Primary School (Standard):     
□ [1] 1   □ [2] 2    □ [3] 3     □ [4] 4   
□ [5] 5   □ [6] 6    □ [7] 7     □ [8] 8  
 
Secondary school (Form):  
□ [9] 1   □ [10] 2   □ [11] 3  □ [12] 4  
 
□ [13] Above secondary school 
 
6 How well can you read Chichewa?  □ [0] Very well     
□ [1] Well  
□ [2] Somewhat  
□ [3] Not at all 
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7 How well can you write Chichewa?  □ [0] Very well     
□ [1] Well  
□ [2] Somewhat  
□ [3] Not at all 
8 How well can you read English?  □ [0] Very well  
□ [1] Well  
□ [2] Somewhat  
□ [3] Not at all 
9 How well can you write English?  □ [0] Very well  
□ [1] Well  
□ [2] Somewhat  
□ [3] Not at all 
10 Was subject able to sign their name 
on the consent? 
 □ [1] Yes □ [0] No 
11 What is your tribe?  
□ [0] Chewa                   
□ [1] Tumbuka                
□ [2] Yao                        
□ [3] Sena    
□ [4] Lomwe  
 
□ [5] Ngoni 
□ [6] Tonga 
□ [7] Nkhonde 
□ [8] Other 
 
□ [99] Don’t know 
12 Are you currently earning an income?  □ [1] Yes □ [0] No  skip to #14 
13 What do you do to earn an income? (mark all that apply)  
□ [1] Taxi driver                   
□ [2] Truck driver               
□ [3] Street vendor                      
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□ [4] Market vendor 
□ [5] Mechanic/petrol station attendant 
□ [6] Bar, tavern, club owner/manager                   
□ [7] Bar, tavern, club employee               
□ [8] Hotel owner/manager                      
□ [9] Hotel employee 
□ [10] Security guard 
□ [11] Hairdresser, barber 
□ [12] Beer/liquor store owner                   
□ [13] CBO/NGO staff               
□ [14] Government staff                      
□ [15] Chief/community leader 
□ [16] Health care worker 
□ [17] Teacher                   
□ [18] Police/military officer               
□ [19] Agricultural work/farmer                      
□ [20] Business/office work 
□ [21] Butcher 
□ [22] Domestic worker/gardener/cleaner                      







14 Do you have electricity at your home?  □ [1] Yes □ [0] No 
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15 Do you have running water at your home?  □ [1] Yes □ [0] No 
16 What is your marital status?  
□ [0] Married    
□ [1] Never married  
□ [2] Separated   
□ [3] Divorced   
□ [4] Widowed  
17 How many living children do you have?  ___ ___ 
18a What area do you live in?  ___________________ 
18b If no area, please indicate Village and nearest area:  ___________________ 
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Part 2. Sexual Behavior 
 
19 
Thinking back to the last month (four weeks), 
how many different partners did you have sex 
with? 
 ___ ___ partners 
20 
Now thinking back to the last three months (12 
weeks), including those you just named, how 
many different partners did you have sex with? 
 ___ ___ partners 
21 How many times during the last week did you have sex?  ___ ___ 
22  How many times during the last month did you have sex?  ___ ___ 
23 How old were you the first time you had sex?  ___ ___ years 
24 Have you ever had a negative HIV test?  □ [1] Yes   □ [0] No end of   
                                      form 
25 If yes, when was your last HIV test?  
 




_____ Months ago 
 
or 
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PARTNER NOTIFICATION STUDY: PARTNER DATA 
 
To be asked of index patient 
Complete a separate form for each named partner 
 
Partner ID: ____ ____ ____ ____ - ____ ____ 
 
Part I. Partner Demographics 
1 Partner age  ___ ___ years 
2 Sex of partner  □ [0] Male  □ [1] Female 
3 How would you describe your relationship to this partner?  
□ [0] Husband/Wife  
□ [1] Live-in partner, not married    
□ [2] Boyfriend/Girlfriend  
□ [3] Regular casual partner – have sex with on an 
ongoing basis  
□ [4] Non-regular casual partner – have sex with 
only once or a few times  
□ [5] Sex worker/prostitute/bargirl/freelancer  
4 When was the first time you had sex with this partner?  
___ ___ days ago  or 
 
___ ___ months ago or 
 
___ ___ years ago 
5 When was the last time you had sex with this partner?  
___ ___ days ago  
 
Must be less than 90 days ago  
6 
How many times in the month (4 weeks) 
before that did you have sex with this 
partner? 
 ___ ___ times 
7 Do you plan to have sex with this partner again?  □ [1] Yes □ [0] No 
8 Did you use a condom the last time you had sex with this partner?  □ [1] Yes □ [0] No 
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9 
Think back to the last 5 times you had 
sex with this partner.  Of those 5 times, 
how many times did you use a condom? 
 
□ [0] 0  □ [1] 1  □ [2] 2  □  [3] 3    □ [4] 4  □ [5] 5 
 
□ [9] Index has had sex with this partner less 















10a.  Total number of times you have had sex 
with this partner? 
□ [0] 0  □ [1] 1  □ [2] 2  □  [3] 3    □ [4] 4 
 
10b. Number of times you used a condom with 
this partner? 
 
□ [0] 0  □ [1] 1  □ [2] 2  □  [3] 3    □ [4] 4 
11 What is the HIV status of this partner?  
□ [1] Positive   
□ [0] Negative  
□  [2] Don’t Know HIV status of partner  
12 Have you ever experienced violence or physical harm by this partner?  □ [1] Yes □ [0] No 
13 Have you ever been violent or physical harmful to this partner?  □ [1] Yes □ [0] No 
 
Part II. Partner Locator Data 
 
14 Is index able to provide locator information on this partner?  □ [1] Yes □ [0] No 
 
 
Complete Partner Locator Form 
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PARTNER NOTIFICATION STUDY 
PARTNER LOCATOR - MAP FORM     
____________________________________________ 
 



























Y       
N             
 




Occupation:                                                           Employer name:                                                                      
 
Work address:                                                       Tel:                                                          email:                                                                                 
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Best time of day to find them: 
 



























How many partners did index patient name? 
 
(Item 20 from INDEX PATIENT ENROLLMENT) 
 ___ ___  
2 Was a partner data form completed for each partner?  □ [1] Yes   □ [0] No 
3 Number of locator forms completed?  ___ ___ 
 If YES to 2, open randomization assignment envelope 
4 Assigned partner notification method  
  □ [0] Passive referral 
  □ [1] Contract referral  
  □ [2] Provider referral  
5 If randomized to contract referral arm, enter date one week from enrollment date  
___ ___     ___ ___ ___    ___ ___  
 D   D          M    M    M       Y     Y     
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Partner Notification Study: Index Patient Follow-up 
 
1 To be completed by research staff: Number of partners named by index patient: ___ ___ 
 For each partner:   
2a Partner ID  ____ ____ ____ ____ - ____ ____ 
2b Did you notify partner 01?  □ [1] Yes  □ [0] No  
2c How many days after your first visit did you notify them? 
 ___ ___ days 
2d To your knowledge, has partner 01 sought HIV counseling and testing? 
 □ [1] Yes    □ [0] No   □ [2] Don’t Know  
2e If yes, where did they go for HIV counseling and testing? 
 
□ [0] KCH STD (7c)  □ [1] Other location   
□  [2] Don’t Know  
 
If other location, name of location: _______________ 
3a Partner ID  ____ ____ ____ ____ - ____ ____ 
3b Did you notify partner 02?  □ [1] Yes  □ [0] No  
3c How many days after your first visit did you notify them? 
 ___ ___ days 
3d To your knowledge, has partner 02 sought HIV counseling and testing? 
 □ [1] Yes    □ [0] No   □ [2] Don’t Know  
3e If yes, where did they go for HIV counseling and testing? 
 
□ [0] KCH STD (7c)  □ [1] Other location   
□  [2] Don’t Know  
 
If other location, name of location: _______________ 
Use next page for additional partners 
 
Index Patient Clinical Data 
4a WHO clinical stage  □ [1] Stage I       □ [2] Stage II □ [3] Stage III      □ [4] Stage IV  
4b CD4 Count  _____ cells/mm3 
If CD4 <250 or WHO Stage III-IV then refer to Lighthouse Clinic     □ [1] Yes  □ [0] No 
   
 105 
Additional Partner Information  
5a Partner 3 ID  ____ ____ ____ ____ - ____ ____ 
5b Did you notify partner 03?  □ [1] Yes  □ [0] No  
5d How many days after your first visit did you notify them? 
 ___ ___ days 
5e 
To your knowledge, has partner 
03 sought HIV counseling and 
testing? 
 □ [1] Yes    □ [0] No   □ [2] Don’t Know  
5f If yes, where did they go for HIV counseling and testing?  
□ [0] KCH STD (7c)  □ [1] Other location   
□  [2] Don’t Know  
 
If other location, name of location: _______________ 
6a Partner 4 ID  ____ ____ ____ ____ - ____ ____ 
6b Did you notify partner 04?  □ [1] Yes  □ [0] No  
6d How many days after your first visit did you notify them? 
 ___ ___ days 
6e 
To your knowledge, has partner 
04 sought HIV counseling and 
testing? 
 □ [1] Yes    □ [0] No   □ [2] Don’t Know  
6f If yes, where did they go for HIV counseling and testing? 
 
□ [0] KCH STD (7c)  □ [1] Other location   
□  [2] Don’t Know  
 
If other location, name of location: _______________ 
7a Partner 5 ID  ____ ____ ____ ____ - ____ ____ 
7b Did you notify partner 05?  □ [1] Yes  □ [0] No  
7d How many days after your first visit did you notify them? 
 ___ ___ days 
7e 
To your knowledge, has partner 
05 sought HIV counseling and 
testing? 
 □ [1] Yes    □ [0] No   □ [2] Don’t Know  
7f If yes, where did they go for HIV counseling and testing?  
□ [0] KCH STD (7c)  □ [1] Other location   
□  [2] Don’t Know  
 
If other location, name of location: _______________ 
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PARTNER NOTIFICATION STUDY: SOCIAL HARMS TO INDEX 
 
 
Item Question  Response 
1 
Since your last study visit, have you experienced 
any problems with the following people as a 
result of being in this study: 
  
1a Your spouse or partner?  □ [1] Yes □ [0] No 
1b People at home/family?  □ [1] Yes □ [0] No 
1c Your friends?  □ [1] Yes □ [0] No 
1d People at work?  □ [1] Yes □ [0] No 
1e People at school?  □ [1] Yes □ [0] No 
1f Your landlord or property owner?  □ [1] Yes □ [0] No 
1g The police?  □ [1] Yes □ [0] No  
1h Other people? Specify:  □ [1] Yes □ [0] No 
 If no to all, end of form   
2. 














3. Has this problem, or any of these problems resulted in:   
3a. 
Emotional harm to you? By emotional harm, I 
mean feeling increased stress, anxiety, worry, or 
depression as a result of this problem. 
 
If Yes, please describe the problem: 
 
□ [1] Yes □ [0] No 








Economic/financial harm to you? For example, 
has this problem resulted in the removal/loss of 
your home, property, or ability to earn income? 
 






□ [1] Yes □ [0] No 
3c. 
Legal harm to you? For example, has this 
problem resulted in legal charges, lawyers, or 
incarceration? 
 





□ [1] Yes □ [0] No 
3d. 
Physical harm to you? For example, has anyone 
physically hurt you as a result of this problem? 
 






□ [1] Yes □ [0] No 
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PARTNER NOTIFICATION STUDY: PARTNER ELIGIBILITY FORM 
 
    
1 
Did participant provide a partner notification card 
or was identity as a partner of an enrolled index 
confirmed by study staff? 
 
□ Yes □No 
 
If No then end of form 
    
2 Partner ID (from notification card and verified with Partner Name Form)  ___ ___ ___ ___ - ___ ___ 
    
 To be asked of participant:   
3 How old are you?   
___ ___ years 
 
If less than 18 then end of form 
    
If participant is less than 18 years old or answered no to question 1 above then participant is not eligible 
    
4 Is partner eligible?  
□ Yes □No 
 
If No then end of form 
    
 To be completed by research staff:   
5 Did the partner provide informed consent for study participation?  
□ Yes □No 
 
If No then end of form 
 
   
Initials  Date 
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HIV Partner Notification Study: Partner Visit Form 
 
KSU ID:  
 
Part I. Partner Demographics 
 
1 Partner ID   ____ ____ ____ ____ - ____ ____ 
2 Date partner attended clinic:  ___ ___     ___ ___ ___    ___ ___   D    D        M    M    M       Y     Y     
3 Partner Sex  □ [0] Male         □ [1] Female  
4 Partner date of birth  ___ ___     ___ ___ ___    ___ ___    D    D        M    M    M        Y     Y      
5 Partner age  ___ ___ years  (partner must be at least 18 years old) 
6 Partner highest level of education you have completed?  
 
□ [0] Never attended school 
 
Primary School (Standard):     
□ [1] 1   □ [2] 2    □ [3] 3     □ [4] 4   
□ [5] 5   □ [6] 6    □ [7] 7     □ [8] 8  
 
Secondary school (Form):  
□ [9] 1   □ [10] 2   □ [11] 3  □ [12] 4  
 
□ [13] Above secondary school 
 
7 What is your marital status?  
□ [0] Married    
□ [1] Never married  
□ [2] Separated   
□ [3] Divorced   
□ [4] Widowed   
   
 110 
8 What area do you live in?  ___________________ 
9 If no area, please indicate Village  ___________________ 
 
Part II. Sexual Behavior 
 
10 Thinking back to the last month (4 weeks), how many different partners did you have sex with?  ___ ___ partners 
11 
Now thinking back to the last three months (12 
weeks), including those you just named, how many 
different partners did you have sex with? 
 ___ ___ partners 
12 How would you describe your relationship to each of these partners?  
12a Partner 1   
□ [0] Husband/Wife  
□ [1] Live-in partner, not married    
□ [2] Boyfriend/Girlfriend  
□ [3] Regular casual partner – have sex with on an ongoing basis  
□ [4] Non-regular casual partner – have sex with only once or a few times  
□ [5] Sex worker/prostitute/bargirl/freelancer  
 
  If only 1 partner in #11, skip to 13 
12b Partner 2  
□ [0] Husband/Wife  
□ [1] Live-in partner, not married    
□ [2] Boyfriend/Girlfriend  
□ [3] Regular casual partner – have sex with on an ongoing basis  
□ [4] Non-regular casual partner – have sex with only once or a few times  
□ [5] Sex worker/prostitute/bargirl/freelancer  
 
  If only 2 partners in #11, skip to 13 
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12c Partner 3  
□ [0] Husband/Wife  
□ [1] Live-in partner, not married    
□ [2] Boyfriend/Girlfriend  
□ [3] Regular casual partner – have sex with on an ongoing basis  
□ [4] Non-regular casual partner – have sex with only once or a few times  
□ [5] Sex worker/prostitute/bargirl/freelancer  
 
  If only 3 partners in #11, skip to 13 
12d Partner 4  
□ [0] Husband/Wife  
□ [1] Live-in partner, not married    
□ [2] Boyfriend/Girlfriend  
□ [3] Regular casual partner – have sex with on an ongoing basis  
□ [4] Non-regular casual partner – have sex with only once or a few times  
□ [5] Sex worker/prostitute/bargirl/freelancer  
13 Have you ever had an HIV test?  □ [1] Yes   □ [0] No   if no skip 14 & 15  
                                     and go straight to 16 
14 When was your last HIV test?  
 




_____ Months ago 
 
or 
_____ Years ago 
 
15 What was the result of your last HIV test?  
□ [1] Reactive  
□ [0] Non-reactive 
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Part III. HIV Testing and STI symptoms 
 




17 Did partner accept HIV testing?  □ [1] Yes □ [0] No 
18 HIV Rapid test result  
□ [1] Reactive  
□ [0] Non-reactive 
□ [2] Discordant 
IF Rapid Test is reactive complete item 19 and item 20 
19 WHO clinical stage  
□ [1] Stage I        □ [2] Stage II  
□  [3] Stage III      □ [4] Stage IV  
20 CD4 Count  _______cells/mm3 
 
 
Itch? □ [1] Yes □ [0] No 
Ulcer? □ [1] Yes □ [0] No 
Dysuria? □ [1] Yes □ [0] No 
Discharge? □ [1] Yes □ [0] No 
Rash? □ [1] Yes □ [0] No 
LAP? □ [1] Yes □ [0] No 
Bubo? □ [1] Yes □ [0] No 
Other? □ [1] Yes □ [0] No 
16 
Did partner experience any of the 
following symptoms is the previous 2 
weeks: 
 
No symptoms □ [1] Yes □ [0] No 
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PARTNER NOTIFICATION STUDY: SOCIAL HARMS TO PARTNER 
 
 
Item Question  Response 
1 
Have you experienced any problems with the 
following people as a result of partner 
notification: 
  
1a Your spouse or partner?  □ [1] Yes □ [0] No 
1b People at home/family?  □ [1] Yes □ [0] No 
1c Your friends?  □ [1] Yes □ [0] No 
1d People at work?  □ [1] Yes □ [0] No 
1e People at school?  □ [1] Yes □ [0] No 
1f Your landlord or property owner?  □ [1] Yes □ [0] No 
1g The police?  □ [1] Yes □ [0] No  
1h Other people? Specify:  □ [1] Yes □ [0] No 
 If no to all, end of form   
2. 














3. Has this problem, or any of these problems resulted in:   
3a. 
Emotional harm to you? By emotional harm, I 
mean feeling increased stress, anxiety, worry, or 
depression as a result of this problem. 
 
If Yes, please describe the problem: 
 
□ [1] Yes □ [0] No 








Economic/financial harm to you? For example, 
has this problem resulted in the removal/loss of 
your home, property, or ability to earn income? 
 






□ [1] Yes □ [0] No 
3c. 
Legal harm to you? For example, has this 
problem resulted in legal charges, lawyers, or 
incarceration? 
 





□ [1] Yes □ [0] No 
3d. 
Physical harm to you? For example, has anyone 
physically hurt you as a result of this problem? 
 






□ [1] Yes □ [0] No 
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PARTNER NOTIFICATION STUDY: REFUSERS   
Item Question  Response 
1 Indicate client sex  □ [0] Male        □ [1] Female 
2 What is your date of birth?  ___ ___     ___ ___ ___    ___ ___   D    D        M    M    M       Y     Y      
3 What is your age?  ___ ___ years 
4 What is the highest level of education you have completed?  
□ [0] Never attended school 
 
Primary School (Standard):     
□ [1] 1   □ [2] 2    □ [3] 3     □ [4] 4   
□ [5] 5   □ [6] 6    □ [7] 7     □ [8] 8  
 
Secondary school (Form): 
□ [9] 1   □ [10] 2   □ [11] 3  □ [12] 4  
 
□ [13] Above secondary school 
5 What is your marital status?  
□ [0] Married    
□ [1] Never married  
□ [2] Separated   
□ [3] Divorced   
□ [4] Widowed   
6a What area do you live in?   
6b If no area, please indicate Village:   
7 Why did you choose not to participate in this research study:   
□ [0] Don’t have time today  
□ [1] Don’t want to notify my partner(s) 
□ [2] Afraid to notify my partner(s)  
□ [3] Don’t want provider to contact my partner(s) 
□ [4] Need more time to think about it 
 
□ [5] Other: _____________________________ 
Use back of form if additional space for 7 is required 
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